RESEARCH PAPER
The interaction between menstrual cycle, Tumour Necrosis Factor alpha receptors and sex hormones in healthy non-obese women – results from an observational study
1
Department of Mother’s and Child’s Health, University of Medical Sciences, Poznań, Poland
2
Department of Educational Medicine, University of Medical Sciences, Poznań, Poland; Higher Vocational State School, Kalisz, Poland
3
Department of Health Informatics and Statistics, Institute of Rural Health, Lublin, Poland
4
Faculty of Pedagogy and Psychology, University of Economics and Innovation, Lublin, Poland
Corresponding author
Anna Włoszczak-Szubzda
Department of Health Informatics and Statistics, Institute of Rural Health, Lublin, Poland
Department of Health Informatics and Statistics, Institute of Rural Health, Lublin, Poland
Ann Agric Environ Med. 2014;21(3):571-575
KEYWORDS
ABSTRACT
There is growing evidence that TNF-alpha and its two receptors play an important role in hormonal regulation, metabolism, inflammation and cancer. The biological effects of TNF-alpha are mediated by two receptors, p55 and p75. The aim of this study was to analyze serum concentrations of p55 and p75 and hormonal status in healthy women during the normal menstrual cycle. Eight women aged 20–22 with regular menstrual cycles were scheduled for examination on 3rd, 8th, 14th and 25th day of their menstrual cycle. We only observed a positive correlation of p75 subunit with prolactin level (correlation coefficient 0.417; p=0.0116) and negative correlation with insulin level (correlation coefficient -0.35; p=0.032) and HOMAIR insulin resistance index correlation coefficient 0.39; p=0.0185). Furthermore, a negative correlation of p55/p75 ratio with prolactin (correlation coefficient -0.42; p=0.0101) and a positive correlations of p55/p75 ratio with insulin level (correlation coefficient 0.43; p=0.008) and HOMAIR insulin resistance factor correlation coefficient 0.45; p=0.0065) were found.
REFERENCES (42)
1.
Oertelt-Prigione S. Immunology and the menstrual cycle. Autoimmun Rev. 2012; 11: 6–7.
2.
Shayesteh J. Genetic and environmental determinants of menstrual characteristics. Indian J Hum Genet. 2012; 18: 187–192.
3.
Kelly RW, King AE, Critchley HO. Cytokine control in human endometrium. Reproduction 2001; 121: 3–19.
4.
Haider S, Knofler M. Human tumour necrosis factor: physiological and pathological roles in placenta and endometrium. Placenta 2009; 30: 111–23.
5.
Okuda K, Sakumoto R. Multiple roles of TNF super family members in corpus luteum function. Reprod Biol Endocrinol. 2003; 1: 95.
6.
Torres MP, Ponnusamy MP, Lakshmanan I, Batra SK. Immunopathogenesis of ovarian cancer. Minerva Med. 2009; 100: 385–400.
7.
Choi DS. Endometrial cancer invasion depends on cancer-derived tumor necrosis factor-alpha and stromal derived hepatocyte growth factor. Int J Cancer. 2009; 124: 2528–2538.
8.
Guerra-Infante FM, Flores-Medina S, López-Hurtado M, Zamora-Ruíz A, Sosa González IE, Narcio Reyes ML, Villagrana-Zessati R. Tumor necrosis factor in peritoneal fluid from asymptomatic infertile women. Arch Med Res. 1999; 30: 138–143.
9.
Medvedev AE, et al. Distinct roles of the two tumor necrosis factor (TNF) receptors in modulating TNF and lymphotoxin alpha effects. J Biol Chem. 1996; 271: 9778–9784.
10.
Olsson I, Gatanaga T, Gullberg U, Lantz M, Granger GA. Tumour necrosis factor (TNF) binding proteins (soluble TNF receptor forms) with possible roles in inflammation and malignancy. Eur Cytokine Netw. 1993; 4: 169–180.
11.
Engelmann H, Holtmann H, Brakebusch C, Avni YS, Sarov I, Nophar Y, Hadas E, Leitner O, Wallach D. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem. 1990; 265: 14497–14504.
12.
Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med. 1992; 175: 323–329.
13.
Chegini N. An inverse relation between the expression of tumor necrosis factor alpha (TNF-alpha) and TNF-alpha receptor in human endometrium. Am J Reprod Immunol. 1999; 42: 297–302.
14.
Onsrud M, Shabana A, Austgulen R, Nustad K. Comparison between soluble tumor necrosis factor receptors and CA125 in peritoneal fluids as a marker for epithelial ovarian cancer. Gynecol Oncol. 1995; 57: 183–187.
15.
Opala T, Rzymski P, Wilczak M, Woźniak J. Evaluation of soluble tumour necrosis factor alpha receptors p55 and p75 in ovarian cancer patients. Eur J Gynaecol Oncol. 2005; 26: 43–46.
16.
Rzymski P. Tumor Necrosis Factor alpha receptors p55 and p75 and ovarian cancer – state-of-the-art research and clinical implications. Arch Med Sci. 2005; 1: 3–7.
17.
Rzymski P, Opala T, Wilczak M, Woźniak J, Sajdak S. Serum tumor necrosis factor alpha receptors p55/p75 ratio and ovarian cancer detection. Int J Gynaecol Obstet. 2005; 88: 292–298.
18.
Buks J, Wilczak M, Rzymski P, Opala T. Do soluble p55 and p75 TNF-α receptor concentrations play a role in women with primary sterility? Arch Med Sci. 2010; 6: 264–269.
19.
Hunt JA. Tumor necrosis factors: pivotal components of pregnancy? Biol Reprod. 1996; 54: 554–562.
20.
von Wolff M, Classen-Linke I, Heid D, Krusche CA, Beier-Hellwig K, Karl C, Beier HM. Tumour necrosis factor-alpha (TNF-alpha) in human endometrium and uterine secretion: an evaluation by immunohistochemistry, ELISA and semiquantitative RT-PCR. Mol Hum Reprod. 1999; 5: 146–152.
21.
Fernandez-Real JM, Gutierrez C, Vendrell J, Casamitjana R, Ricart W. Plasma soluble tumor necrosis factor-alpha receptors circulate in proportion to leptin levels during the menstrual cycle in lean but not in obese women. Eur J Endocrinol. 2000; 143: 235–241.
22.
Valdes CT, Elkind-Hirsch KE. Intravenous glucose tolerance test-derived insulin sensitivity changes during the menstrual cycle. J Clin Endocrinol Metab. 1991; 72: 642–646.
23.
Yeung EH, Zhang C, Mumford SL, Ye A, Trevisan M, Chen L, Browne RW, Wactawski-Wende J, Schisterman EF. Longitudinal study of insulin resistance and sex hormones over the menstrual cycle: the BioCycle Study. J Clin Endocrinol Metab. 2010; 95: 5435–5442.
24.
Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Obesity, inflammation and insulin resistance: which role for adipokines. Therapie 2007; 62: 285–292.
25.
Grunfeld C, Feingold KR. The metabolic effects of tumor necrosis factor and other cytokines. Biotherapy 1991; 3: 143–58.
26.
Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995; 95: 2409–2415.
27.
Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA. The expression of TNF alpha by human muscle. Relationship to insulin resistance. J Clin Invest. 1996; 97: 1111–1116.
28.
Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994; 43: 1271–1278.
29.
Argiles JM, Lopez-Soriano J, Lopez-Soriano FJ. Cytokines and diabetes: the final step? Involvement of TNF-alpha in both type I and II diabetes mellitus. Horm Metab Res. 1994; 26: 447–449.
30.
Altinova AE, Toruner F, Bozkurt N, Bukan N, Karakoc A, Yetkin I, Ayvaz G, Cakir N, Arslan M. Circulating concentrations of adiponectin and tumor necrosis factor-alpha in gestational diabetes mellitus. Gynecol Endocrinol. 2007; 23: 161–165.
31.
Stephens JM, Pekala PH. Transcriptional repression of the C EBP-alpha and GLUT4 genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. Regulations is coordinate and independent of protein synthesis. J Biol Chem. 1992; 267: 13580- 13584.
32.
Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996; 271: 665–668.
33.
Fernandez-Real JM, Broch M, Ricart W, Casamitjana R, Gutierrez C, Vendrell J, Richart C. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. Diabetes 1998; 47: 1757–1762.
34.
Vidal S, Cohen SM, Horvath E, Kovacs K, Scheithauer BW, Burguera BG, Lloyd RV. Subcellular localization of leptin in non-tumorous and adenomatous human pituitaries: an immuno-ultrastructural study. J Histochem Cytochem. 2000; 48: 1147–1152.
35.
Friedrichsen S, Harper CV, Semprini S, Wilding M, Adamson AD, Spiller DG, Nelson G, Mullins JJ, White MR, Davis JR. Tumor necrosis factor-alpha activates the human prolactin gene promoter via nuclear factor-kappaB signaling. Endocrinology 2006; 147: 773–7781.
36.
Koike K, Masumoto N, Kasahara K, Yamaguchi M, Tasaka K, Hirota K, Miyake A, Tanizawa O. Tumor necrosis factor-alpha stimulates prolactin release from anterior pituitary cells: a possible involvement of intracellular calcium mobilization. Endocrinology 1991; 128: 2785–2790.
37.
Gaillard RC, Turnill D, Sappino P, Muller AF. Tumor necrosis factor alpha inhibits the hormonal response of the pituitary gland to hypothalamic releasing factors. Endocrinology 1990; 127: 101–106.
38.
Milenkovic L, Rettori V, Snyder GD, Beutler B, McCann SM. Cachectin alters anterior pituitary hormone release by a direct action in vitro. Proc Natl Acad Sci USA. 1989; 86: 2418–2422.
39.
Freeman ME, Yicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000; 80: 1523–1631.
40.
Kansra S, Yamagata S, Sneade L, Foster L, Ben-Jonathan N. Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol Cell Endocrinol. 2005; 239: 27–36.
41.
Adamson AD, Friedrichsen S, Semprini S, Harper CV, Mullins JJ, White MR, Davis JR. Human prolactin gene promoter regulation by estrogen: convergence with tumor necrosis factor-alpha signaling. Endocrinology 2008; 149: 687–694.
42.
Zaldivar V, Magri ML, Zárate S, Jaita G, Eijo G, Radl D, Ferraris J, Pisera D, Seilicovich A Estradiol Increases the Expression of TNF-alpha and TNF Receptor 1 in Lactotropes. Neuroendocrinology 2011; 93: 106–113.
| eISSN: | 1898-2263 |
| ISSN: | 1232-1966 |
Improvement of visual identification of the journal - task financed under the agreement No. 618/P-DUN/2019 by the Minister of Science and Higher Education allocated to the activities of disseminating science.
Generation of the DOI (Digital Object Identifier) - task financed under the agreement No. 618/P-DUN/2019 by the Minister of Science and Higher
© 2006-2024 Journal hosting platform by Bentus
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
